Published in Diabetes on September 16, 2008
AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol (2010) 1.93
Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med (2015) 1.82
The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol (2009) 1.66
Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front Biosci (Landmark Ed) (2009) 1.51
G protein-coupled receptor kinase 2 plays a relevant role in insulin resistance and obesity. Diabetes (2010) 1.32
Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia. J Cachexia Sarcopenia Muscle (2011) 1.06
Links between insulin resistance, adenosine A2B receptors, and inflammatory markers in mice and humans. Diabetes (2011) 1.06
AMPK and Exercise: Glucose Uptake and Insulin Sensitivity. Diabetes Metab J (2013) 1.03
Weight cycling enhances adipose tissue inflammatory responses in male mice. PLoS One (2012) 1.02
Effect of lipopolysaccharide on inflammation and insulin action in human muscle. PLoS One (2013) 0.99
AMP-activated protein kinase and metabolic control. Handb Exp Pharmacol (2011) 0.99
Protein tyrosine phosphatase 1B modulates GSK3β/Nrf2 and IGFIR signaling pathways in acetaminophen-induced hepatotoxicity. Cell Death Dis (2013) 0.97
HGK/MAP4K4 deficiency induces TRAF2 stabilization and Th17 differentiation leading to insulin resistance. Nat Commun (2014) 0.97
Insulin resistance and inflammation markers in myocardial infarction. J Inflamm Res (2013) 0.93
Metabolic response to endotoxin in vivo in the conscious mouse: role of interleukin-6. Metabolism (2010) 0.90
The Genetics of PTPN1 and Obesity: Insights from Mouse Models of Tissue-Specific PTP1B Deficiency. J Obes (2012) 0.89
The chaperone balance hypothesis: the importance of the extracellular to intracellular HSP70 ratio to inflammation-driven type 2 diabetes, the effect of exercise, and the implications for clinical management. Mediators Inflamm (2015) 0.86
Oxidized LDL impair adipocyte response to insulin by activating serine/threonine kinases. J Lipid Res (2009) 0.86
A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice. Br J Pharmacol (2014) 0.86
Human skeletal myotubes display a cell-autonomous circadian clock implicated in basal myokine secretion. Mol Metab (2015) 0.85
Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice. Dis Model Mech (2015) 0.84
Opposite cross-talk by oleate and palmitate on insulin signaling in hepatocytes through macrophage activation. J Biol Chem (2015) 0.81
Interleukin-6 amplifies glucagon secretion: coordinated control via the brain and pancreas. Am J Physiol Endocrinol Metab (2014) 0.81
Necrotic renal epithelial cell inhibits renal interstitial fibroblast activation: role of protein tyrosine phosphatase 1B. Am J Physiol Renal Physiol (2013) 0.80
MARK/Par1 Kinase Is Activated Downstream of NMDA Receptors through a PKA-Dependent Mechanism. PLoS One (2015) 0.80
Insulin resistance and muscle metabolism in chronic kidney disease. ISRN Endocrinol (2013) 0.79
Deletion of interleukin-6 improves pyruvate tolerance without altering hepatic insulin signaling in the leptin receptor-deficient mouse. Metabolism (2011) 0.79
Metabolic phenotype and adipose tissue inflammation in patients with chronic obstructive pulmonary disease. Mediators Inflamm (2010) 0.79
A single bout of exercise increases the expression of glucose but not fatty acid transporters in skeletal muscle of IL-6 KO mice. Lipids (2012) 0.79
Genetics of non-alcoholic fatty liver disease: From susceptibility and nutrient interactions to management. World J Hepatol (2016) 0.78
Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities. Int J Mol Sci (2014) 0.77
Single administration of recombinant IL-6 restores the gene expression of lipogenic enzymes in liver of fasting IL-6-deficient mice. Br J Pharmacol (2016) 0.76
IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis. Acta Neuropathol Commun (2015) 0.76
Interleukin-6 increases the expression and activity of insulin-degrading enzyme. Sci Rep (2017) 0.75
The SLIM Study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia. J Clin Lipidol (2009) 0.75
Altered Interleukin-10 Signaling in Skeletal Muscle Regulates Obesity-Mediated Inflammation and Insulin Resistance. Mol Cell Biol (2016) 0.75
A Triterpenoid Inhibited Hormone-Induced Adipocyte Differentiation and Alleviated Dexamethasone-Induced Insulin Resistance in 3T3-L1 adipocytes. Nat Prod Bioprospect (2015) 0.75
PI3K-GLUT4 Signal Pathway Associated with Effects of EX-B3 Electroacupuncture on Hyperglycemia and Insulin Resistance of T2DM Rats. Evid Based Complement Alternat Med (2016) 0.75
Shortcuts to a functional adipose tissue: The role of small non-coding RNAs. Redox Biol (2017) 0.75
Skeletal muscle insulin resistance in hamsters with diabetes developed from obesity is involved in abnormal skeletal muscle LXR, PPAR and SREBP expression. Exp Ther Med (2016) 0.75
Chronic IL-6 Administration Desensitizes IL-6 Response in Liver, Causes Hyperleptinemia and Aggravates Steatosis in Diet-Induced-Obese Mice. PLoS One (2016) 0.75
Alantolactone Improves Prolonged Exposure of Interleukin-6-Induced Skeletal Muscle Inflammation Associated Glucose Intolerance and Insulin Resistance. Front Pharmacol (2017) 0.75
Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy. J Nephrol (2017) 0.75
Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest (1995) 9.59
LKB1-dependent signaling pathways. Annu Rev Biochem (2006) 5.91
Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab (2001) 5.76
Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol (2000) 4.64
Interleukin-6-deficient mice develop mature-onset obesity. Nat Med (2002) 4.47
Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes (2004) 4.37
Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J (2005) 4.31
The GLUT4 glucose transporter. Cell Metab (2007) 4.30
Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol (2004) 3.79
Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem (2003) 3.57
Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest (2001) 3.41
Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes (2002) 2.85
Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes (2006) 2.80
Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes (2005) 2.61
Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am J Physiol Endocrinol Metab (2004) 2.61
Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. Diabetes (2006) 2.24
Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo. J Biol Chem (2008) 2.08
Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab (2002) 1.98
Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J Biol Chem (2006) 1.96
Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J Biol Chem (2003) 1.92
AMP-activated protein kinase and the regulation of glucose transport. Am J Physiol Endocrinol Metab (2006) 1.80
Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun (2003) 1.79
Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes (2004) 1.73
Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem (2004) 1.69
Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B. Mol Cell Biol (2007) 1.66
Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes (2000) 1.58
Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest (1997) 1.58
Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. J Biol Chem (2007) 1.53
Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes (2006) 1.44
IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab (2002) 1.43
Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol (2006) 1.43
Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes (2004) 1.43
Palmitate induces tumor necrosis factor-alpha expression in C2C12 skeletal muscle cells by a mechanism involving protein kinase C and nuclear factor-kappaB activation. Endocrinology (2005) 1.42
Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes (2007) 1.37
Adrenaline is a critical mediator of acute exercise-induced AMP-activated protein kinase activation in adipocytes. Biochem J (2007) 1.31
Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia (2008) 1.25
Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J Biol Chem (2004) 1.25
Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. J Clin Invest (1996) 1.14
Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance. J Biol Chem (2007) 1.12
Retracted Immunohistochemical detection of interleukin-6 in human skeletal muscle fibers following exercise. FASEB J (2003) 1.12
C2C12 myocytes lack an insulin-responsive vesicular compartment despite dexamethasone-induced GLUT4 expression. Am J Physiol Endocrinol Metab (2002) 1.08
Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-alpha-induced insulin resistance. Diabetes (2007) 1.05
Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats. Br J Pharmacol (2005) 0.99
Cutting edge: IL-4 induces suppressor of cytokine signaling-3 expression in B cells by a mechanism dependent on activation of p38 MAPK. J Immunol (2005) 0.95
Activation of liver X receptors promotes lipid accumulation but does not alter insulin action in human skeletal muscle cells. Diabetologia (2006) 0.93
Depot-specific variation in protein-tyrosine phosphatase activities in human omental and subcutaneous adipose tissue: a potential contribution to differential insulin sensitivity. J Clin Endocrinol Metab (2001) 0.88
Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats. Diabetologia (2004) 0.87
Liver X receptor agonists ameliorate TNFalpha-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression. Diabetologia (2006) 0.85
Activation of opioid mu-receptors by loperamide to improve interleukin-6-induced inhibition of insulin signals in myoblast C2C12 cells. Diabetologia (2005) 0.81
Roles of skeletal muscle and peroxisome proliferator-activated receptors in the development and treatment of obesity. Endocr Rev (2006) 0.79
Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem (2008) 1.80
Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem (2004) 1.69
G protein-coupled receptor kinase 2 plays a relevant role in insulin resistance and obesity. Diabetes (2010) 1.32
Adenosine 5'-monophosphate-activated protein kinase-mammalian target of rapamycin cross talk regulates brown adipocyte differentiation. Endocrinology (2010) 1.18
Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-alpha-induced insulin resistance. Diabetes (2007) 1.05
Sprouty-2 overexpression in C2C12 cells confers myogenic differentiation properties in the presence of FGF2. Mol Biol Cell (2005) 1.05
Insulin restores differentiation of Ras-transformed C2C12 myoblasts by inducing NF-kappaB through an AKT/P70S6K/p38-MAPK pathway. Oncogene (2002) 1.02
Rosiglitazone and retinoic acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal primary brown adipocytes. J Biol Chem (2002) 1.00
c-Jun N-terminal kinase 1/2 activation by tumor necrosis factor-alpha induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists. J Clin Endocrinol Metab (2009) 1.00
Hyperinsulinemia induces insulin resistance on glucose and lipid metabolism in a human adipocytic cell line: paracrine interaction with myocytes. J Clin Endocrinol Metab (2008) 0.99
Molecular mechanisms involved in obesity-associated insulin resistance: therapeutical approach. Arch Physiol Biochem (2009) 0.95
Metabolic rescue of obese adipose-derived stem cells by Lin28/Let7 pathway. Diabetes (2013) 0.91
Human aquaporin-11 is a water and glycerol channel and localizes in the vicinity of lipid droplets in human adipocytes. Obesity (Silver Spring) (2014) 0.89
TWEAK prevents TNF-α-induced insulin resistance through PP2A activation in human adipocytes. Am J Physiol Endocrinol Metab (2013) 0.88
ATP-sensitive K(+) channels regulate the concentrative adenosine transporter CNT2 following activation by A(1) adenosine receptors. Mol Cell Biol (2004) 0.87
Ceramide mediates TNF-alpha-induced insulin resistance on GLUT4 gene expression in brown adipocytes. Arch Physiol Biochem (2006) 0.87
Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance. J Clin Endocrinol Metab (2014) 0.85
The rise of soluble TWEAK levels in severely obese subjects after bariatric surgery may affect adipocyte-cytokine production induced by TNFα. J Clin Endocrinol Metab (2013) 0.84
G Protein-coupled receptor kinase 2 (GRK2): A novel modulator of insulin resistance. Arch Physiol Biochem (2011) 0.84
GRK2 contribution to the regulation of energy expenditure and brown fat function. FASEB J (2012) 0.83
Insulin and dexamethasone induce GLUT4 gene expression in foetal brown adipocytes: synergistic effect through CCAAT/enhancer-binding protein alpha. Biochem J (2003) 0.80
Nuclear exclusion of forkhead box O and Elk1 and activation of nuclear factor-kappaB are required for C2C12-RasV12C40 myoblast differentiation. Endocrinology (2007) 0.78
A new era for brown adipose tissue: New insights into brown adipocyte function and differentiation. Arch Physiol Biochem (2011) 0.77
Cord blood FGF21 in gestational diabetes and its relationship with postnatal growth. Acta Diabetol (2015) 0.75